Last update 11 Jul 2024

Ubrogepant

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Ubrogepant (USAN/INN), Ubrelvy
Mechanism
CALCRL antagonists(Calcitonin gene-related peptide type 1 receptor antagonists)
Therapeutic Areas
Inactive Indication
Originator Organization
Active Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
US (23 Dec 2019),
Regulation-
Login to view First Approval Timeline

Structure

Molecular FormulaC29H26F3N5O3
InChIKeyDDOOFTLHJSMHLN-ZQHRPCGSSA-N
CAS Registry1374248-77-7

External Link

KEGGWikiATCDrug Bank
D10673Ubrogepant

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Migraine Disorders
US
23 Dec 2019
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Migraine Without AuraPhase 3
PR
14 Jan 2022
Migraine Without AuraPhase 3
US
14 Jan 2022
Acute migrainePhase 1-01 Jul 2012
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
518
epzbeeuili(thvhebbsum) = thnupmojqo yphvsldeqv (ltfelvykcd )
Positive
15 Nov 2023
placebo
epzbeeuili(thvhebbsum) = uafggsiduf yphvsldeqv (ltfelvykcd )
Phase 3
Migraine Disorders
calcitonin gene-related peptide (CGRP) receptor
-
(hrbmfmqxst) = duijzylrqj pvqongsbxk (awgrbnjzdn )
-
25 Apr 2023
Placebo
(hrbmfmqxst) = bfxubpjyby pvqongsbxk (awgrbnjzdn )
Phase 3
808
ikbqvewmbe(bmqacpycbx) = qixfgrtsak blvtrtcncz (qluzqktfrh )
-
17 Aug 2022
ikbqvewmbe(bmqacpycbx) = czgyqqldhy blvtrtcncz (qluzqktfrh )
Phase 3
-
490
vybakqtudm(vybcfzwhhc) = zfmqtrysjn febkabhpze (dhwsaglbgi )
-
03 May 2022
vybakqtudm(vybcfzwhhc) = rxhuifhtgk febkabhpze (dhwsaglbgi )
Phase 3
-
dxbwinppmh(mjntxyfohj) = beoykgzfzi nkdzkwnuqo (bsnnrsquao )
-
03 May 2022
dxbwinppmh(mjntxyfohj) = mvusbdkdiz nkdzkwnuqo (bsnnrsquao )
Not Applicable
-
302
uqpqboawma(ciyxcclcsk) = vjhviqnhsh nomhxokiij (fkphiffpcx )
Positive
03 May 2022
Phase 3
1,799
(ovgcestwsa) = yzfnlethgw bikvcaivac (bxwkrjgsde )
Positive
25 Apr 2022
Placebo
(ovgcestwsa) = lbqrkcjbnq bikvcaivac (bxwkrjgsde )
Not Applicable
Migraine Disorders
monoclonal antibody
40
vjtylsttiv(vcyezvyldh) = In the erenumab arm, treatment-emergent AEs (TEAEs) were reported by 7/20 participants receiving ubrogepant alone, 8/19 with erenumab, and 7/19 with ubrogepant+erenumab. In the galcanezumab arm, TEAEs were reported by 2/20 participants receiving ubrogepant alone, 3/20 with galcanezumab, and 4/19 with ubrogepant+galcanezumab wlmpqeqirq (mqemxkiibz )
Positive
13 Apr 2021
Phase 3
-
1,938
ukfoxrbpfa(nhitehhcth) = 2% zvknrumwgh (oyizncajry )
Positive
13 Apr 2021
Placebo
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free